Paper18201212
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
Vilsbøll T and 10 others. Diabet Med, 2008. Cited by 177 papers, by iCite.
Cite this record
ConductScience Library. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Papers, record 18201212. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18201212
- Disease
- type 2 diabetes mellitus613 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
- PubMed
- Publication types
- Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Glucagon-Like Peptide 1 | Major topic |
| Hypoglycemic Agents | Major topic |
| Islets of Langerhans | Major topic |
| Receptors, Glucagon | Major topic |
| C-Peptide | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Incretins | |
| Insulin Resistance | |
| Liraglutide | |
| Male | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00154401 | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Results |
Source ClinicalTrials.gov
Cited by70
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 177 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41440034 | Metabolic Stress and Adaptation in Pancreatic β-Cells to Hypoxia: Mechanisms, Modulators, and Implications for Transplantation. | Cells | 2025 | https://conductscience.org/library/papers/41440034 | PubMed |
| 40869417 | Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40869417 | PubMed |
| 40181228 | How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. | Obes Rev | 2025 | https://conductscience.org/library/papers/40181228 | PubMed |
| 39598383 | GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39598383 | PubMed |
| 39044524 | The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats. | J Prev Alzheimers Dis | 2024 | https://conductscience.org/library/papers/39044524 | PubMed |
| 38211595 | Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. | Diabetes Care | 2024 | https://conductscience.org/library/papers/38211595 | PubMed |
| 37707701 | Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial. | Diabetes Ther | 2023 | https://conductscience.org/library/papers/37707701 | PubMed |
| 37313232 | Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. | touchREV Endocrinol | 2023 | https://conductscience.org/library/papers/37313232 | PubMed |
| 36498669 | Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. | J Clin Med | 2022 | https://conductscience.org/library/papers/36498669 | PubMed |
| 36349778 | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. | Obes Facts | 2023 | https://conductscience.org/library/papers/36349778 | PubMed |
| 34114119 | Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function. | Handb Exp Pharmacol | 2022 | https://conductscience.org/library/papers/34114119 | PubMed |
| 33626072 | Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. | PLoS One | 2021 | https://conductscience.org/library/papers/33626072 | PubMed |
| 33473176 | Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. | Int J Obes (Lond) | 2021 | https://conductscience.org/library/papers/33473176 | PubMed |
| 33413317 | The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. | BMC Endocr Disord | 2021 | https://conductscience.org/library/papers/33413317 | PubMed |
| 33190640 | Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. | BMC Med | 2020 | https://conductscience.org/library/papers/33190640 | PubMed |
| 32348108 | Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor. | ACS Chem Biol | 2020 | https://conductscience.org/library/papers/32348108 | PubMed |
| 31583380 | The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. | J Obes Metab Syndr | 2019 | https://conductscience.org/library/papers/31583380 | PubMed |
| 31164926 | Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. | Diabetol Metab Syndr | 2019 | https://conductscience.org/library/papers/31164926 | PubMed |
| 31031702 | The Discovery and Development of Liraglutide and Semaglutide. | Front Endocrinol (Lausanne) | 2019 | https://conductscience.org/library/papers/31031702 | PubMed |
| 29895889 | Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease. | Sci Rep | 2018 | https://conductscience.org/library/papers/29895889 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| LIRAGLUTIDE | CHEMBL4084119 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4084119 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/18201212
GET https://conductscience.org/api/papers/v1/18201212/cited_by?page=2